Mitochondria as a Critical Target of COVID-19 Pathogenesis
DOI:
https://doi.org/10.20455/ros.2022.n.807Abstract
Over the past two years, findings from several research studies published in highly influential journals pointed to a critical involvement of mitochondria in the pathophysiology of SARS-CoV2 infections. Among the most exciting findings are the involvement of (i) the “mitochondrial ROS–HIF-1α –glycolysis” axis, (ii) the “cGAS–STING” signaling, and (iii) the “mitochondrial apoptotic cell death” pathway.
(First online: March 3, 2022)
REFERENCES
- Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116(2):205–19. doi: https://dx.doi.org/10.1016/s0092-8674(04)00046-7
- Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 2014; 94(3):909–50. doi: https://dx.doi.org/10.1152/physrev.00026.2013
- Ros EO. Mitochondrial ROS take center stage in immune regulation. React Oxyg Species (Apex) 2021; 11:n9–n10. doi: https://dx.doi.org/10.20455/ros.2021.n.809
- Weinberg SE, Sena LA, Chandel NS. Mitochondria in the regulation of innate and adaptive immunity. Immunity 2015; 42(3):406–17. doi: https://dx.doi.org/10.1016/j.immuni.2015.02.002
- Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/glycolysis-dependent axis. Cell Metab 2020; 32(3):437–46 e5. doi: https://dx.doi.org/10.1016/j.cmet.2020.07.007
- Domizio JD, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K, et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature 2022. doi: https://dx.doi.org/10.1038/s41586-022-04421-w
- Simpson DS, Pang J, Weir A, Kong IY, Fritsch M, Rashidi M, et al. Interferon-gamma primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway. Immunity 2022. doi: https://dx.doi.org/10.1016/j.immuni.2022.01.003

Downloads
Published
How to Cite
Issue
Section
License
Submission of an original manuscript to the Journal will be taken to mean that it represents original work not previously published; that it is not being considered elsewhere for publication; that the author(s) agrees to assign copyright to the Journal upon acceptance for publication in the Journal, and if accepted for publication, it will be published in the digital format (PDF) and/or in print and it will not be published elsewhere in the same form, for commercial purposes, in any language, without the consent of the Publisher.